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Abstract
The emergence of effective radionuclide therapeutics, such as radium-223 dichloride, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-PSMA ligands, over the last 10 years is
driving a rapid expansion in molecular radiotherapy (MRT) research. Clinical trials that are underway will help to deﬁne optimal dosing protocols and identify
groups of patients who are likely to beneﬁt from this form of treatment. Clinical investigations are also being conducted to combine new MRT agents with other
anticancer drugs, with particular emphasis on DNA repair inhibitors and immunotherapeutics. In this review, the case is presented for combining MRT with
external beam radiotherapy (EBRT). The technical and dosimetric challenges of combining two radiotherapeutic modalities have impeded progress in the past.
However, the need for research into the speciﬁc radiobiological effects of radionuclide therapy, which has lagged behind that for EBRT, has been recognised. This,
together with innovations in imaging technology, MRT dosimetry tools and EBRT hardware, will facilitate the future use of this important combination of
treatments.
! 2021 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
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Introduction
External beam radiotherapy (EBRT) has been a mainstay of
cancer medicine for over a century. Molecular radiotherapy
(MRT), introduced in the 1940s with the use of 131-iodine for
thyroid cancer, also has a long-established place among cancer therapies. Given the longevity of both treatments, it is
surprising that there has been little research into their combined use and remarkably few examples of their pairing in
clinical protocols [1]. The cardinal mechanism of cell killing by
both treatments is ionising radiation-induced irreparable
DNA strand breaks. However, the two modalities cause profoundly different biological effects, resulting from their
dissimilar modes of administration, dose rates, dose
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distributions and molecular mechanisms of cytotoxicity.
Recognition of the efﬁcacy of radiopharmaceuticals, such as
[177Lu]Lu-DOTA-TATE for neuroendocrine tumours and radiolabelled PSMA ligands for prostate cancer, is driving a
renewed research effort, including questions about how best
to combine MRT with other treatments [2e5]. A signiﬁcant
obstacle to combining EBRT and MRT has been the lack of a
dosimetric framework that relates the spatiotemporal pattern
and amount of energy deposited by each treatment to the
total biological effect of the two together [6,7]. This has been
compounded by there being no recommendation, until
recently, to tailor the amount of administered radioactivity in
MRT treatments to individual patients. This has been partly
remedied through the implementation of international directives recommending that MRT be individually planned,
and its delivery veriﬁed, usually through single-photon
emission computed tomography (SPECT) or positron emission tomography (PET) imaging [8,9]. In this review, MRT
is deﬁned as the use of systemically or regionally administered radiopharmaceuticals that incorporate b-electron-, a-
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particle- or Auger electron-emitting radionuclides for cancer
therapy. Many such radionuclides also emit g-photons or
positrons, enabling SPECT or PET imaging.

Rationale for Combining External Beam
Radiotherapy and Molecular Radionuclide
Therapy
Spatial Co-operation
The concept of spatial co-operation was ﬁrst invoked to
describe the advantages of combining EBRT with chemotherapy: EBRT can debulk a dominant tumour mass while
co-administered systemic therapy contributes to the control of the primary cancer and simultaneously eradicates
smaller widespread deposits [10,11]. As MRT is delivered
systemically or, less frequently, regionally, this principle
also applies to the combination of EBRT and MRT. This
approach was shown to be technically feasible in the
treatment of hepatocellular cancer (HCC), where multiple
intrahepatic tumours were targeted using yttrium-90 selective internal radiation therapy ([90Y]Y-SIRT), which involves the administration of radiolabelled microspheres
into the hepatic artery, combined with EBRT to bulk lesions.
Two studies demonstrated methods for combining the
absorbed dose from [90Y]Y-SIRT with that of EBRT [12,13].
Using the biological effective dose (BED) which is a quantitative measure of the biological effect of a radiotherapy
treatment taking into account dose per fraction or dose rate
and total dose, it was possible to compute the combined
dose from both sources (Figure 1). These studies concluded
that EBRT and SIRT can be given safely to patients with HCC.
In another combination study, 11 patients with relapsed or
refractory follicular lymphoma were treated ﬁrst with EBRT
to sites of bulk disease followed by [90Y]Y-ibritumomab
tiuxetan ([90Y]Y-IT). The median progression-free survival
was 17.5 months, which compared favourably with [90Y]YIT alone; it was concluded that EBRT helped to prevent
relapse at sites of bulk disease [14].
Normal Tissue Protection
Another advantage of combining MRT and EBRT is that
the organs at risk of toxic effects differ, making radiationabsorbed dose escalation to tumour possible while
meeting normal organ dose constraints. In EBRT, beams
often traverse healthy tissue to reach a tumour. To minimise
off-target effects, conformal techniques, such as intensitymodulated radiotherapy or rotational arc therapy, spread
the off-target dose over a large volume. In MRT, radionuclides irradiate tissue isotropically, such that the deposited
dose falls off rapidly with distance from the source, obeying
the inverse-square law. Although speciﬁc targeting can be
imperfect, an advantage of MRT is that adjacent tissues are
spared. The organs at risk in the case of EBRT are those
closest to the tumour, whereas MRT toxicity depends on the
pharmacokinetics of the radiopharmaceutical and its

pattern of accumulation in normal organs. For example, dry
mouth is a common side-effect of [177Lu]Lu-PSMA ligands
as they concentrate in the salivary glands [15]. In general,
normal organs that are vulnerable following MRT are organs
of excretion, particularly the kidneys, and the bone marrow,
which may be irradiated as the radiopharmaceutical circulates freely post-injection [16,17].
Enhancement of Tumour Response
In addition to spatial co-operation and non-overlapping
toxicity proﬁles, interactions between EBRT and MRT may
lead to sensitisation of a tumour to one agent by the other,
resulting in super-additivity. One example is their combined effect on the immune system. EBRT induces a
plethora of immune-activating mechanisms and emerging
evidence shows that MRT can also increase sensitivity to
cytotoxic immune cells and promote lymphocyte recruitment and activation [18,19]. Early reports indicate that the
timing of changes in the immune landscape may differ for
the two treatments; it is plausible that these differences
could be harnessed for therapeutic gain [19,20]. Another
exploitable interaction is the increase in blood ﬂow and
vessel permeability after exposure to EBRT which, when
immediately preceded or followed by MRT, can enhance
intra-tumoural accumulation of radioactivity [21,22]. Using
dynamic contrast-enhanced magnetic resonance imaging of
SK-N-SH (human neuroblastoma) xenografts in mice,
Corroyer-Dulmont et al. [23] showed a signiﬁcant increase
in intra-tumoural vessel permeability up to 72 h following
EBRT. When [131I]I-MIBG was administered 24 h after EBRT,
there was a more than two-fold increase in the accumulation of radioactivity and radiation absorbed dose in tumour
compared with single-agent MRT. A similar observation was
made by Dietrich et al. [24] when [90Y]Y-cetuximab was
administered during a course of fractionated EBRT applied
to FaDu (human head and neck squamous cell carcinoma)
xenografts in mice. These investigators found that tumour
uptake of cetuximab correlated with the pre-applied dose
of external radiation (up to a threshold of 24 Gy), showing
complete tumour control in animals receiving both [90Y]Ycetuximab (2.8 MBq) and EBRT (20e120 Gy, in 30 fractions).
It may also be possible to exploit molecular alterations
induced in cancer cells by one modality to enhance the
toxicity of the other. In one example, the cytotoxicity of an
investigational radiolabelled antibody, [111In]In-antigH2AX-Tat, was potentiated by prior EBRT. In this case, the
molecular target, gH2AX, a marker of DNA double-strand
breaks, was induced by external radiation, leading to
enhanced accumulation of [111In]In-anti-gH2AX-Tat, which
then caused ampliﬁcation of the pre-existing EBRT-induced
DNA damage [25]. In another example, EBRT-induced somatostatin receptor type 2 expression in neuroendocrine
and small cell lung cancers resulted in greater accumulation
of [177Lu]Lu-DOTA-Tyr3-octreotate [26,27]. The opposite
sequencing of the two treatments to achieve radiosensitisation of one by the other is also possible: an
experimental oligonucleotide-based radiopharmaceutical
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Fig 1. Biological effective dose (BED) maps for two representative patients who received external beam radiotherapy (EBRT) followed by
yttrium-90 selective internal radiation therapy ([90Y]Y-SIRT) for hepatocellular carcinoma. The rows illustrate the BED calculated from EBRT,
[90Y]Y-SIRT and their voxel-wise sum determined through a contour and intensity-based deformation using MIM SurePlan LiverY90 (version
6.9.4; MIM Software Inc., OH, USA). To aid in visualising treated areas exceeding a 40 Gy physical dose constraint to normal liver, the SIRT and
sum BED rows are displayed using differing scaling. In addition, tumour tissues had different BED scaling than the normal tissue due to the
differing radiosensitivity parameters of each tissue. Liver is contoured in blue and tumour in magenta. Reproduced with permission from [12].

directed against telomerase RNA, hTR, has the fringe beneﬁt
of sensitisation to subsequent EBRT [28,29], as inhibition of
telomerase enhances radiotoxicity [30,31].

images, to delineate tumours for EBRT planning purposes
[32,33], as well as informing MRT dose selection [34].

Theranostic Beneﬁts

Radiobiological Considerations

Theranostic radiopharmaceuticals are designed to have
both therapeutic and imaging capability. This is achieved
by labelling the carrier molecule with a positron- or gemitting radionuclide for imaging and exchanging it for a
therapeutic radionuclide (b-electron- or a-emitter) for
treatment if sufﬁcient tumour targeting is identiﬁed.
Increasingly, companion diagnostics are used to assess
biodistribution, including tumour uptake, to assist planning of MRT. It has been suggested that in combined MRT
plus EBRT regimens, these preparatory images could, if
tumour uptake is sufﬁcient, be used, together with CT

Radiobiological modelling of MRT is often based on
extrapolation of data from EBRT; however, EBRT and MRT
are not radiobiologically equivalent [6]. The need for better
understanding of the radiobiological effects of MRT has
been highlighted recently by expert commentators
[35e37]. One fundamental difference is that EBRT is delivered at a high dose rate, inﬂicting each fraction of the
tumoricidal dose in a few minutes (z1 Gy/min). In contrast,
MRT is a low dose rate treatment (z0.01 Gy/min), delivering dose over a protracted period, dictated by the physical
half-life of the radionuclide and the extent of accumulation
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and rate of efﬂux from the tumour or normal organs.
Several studies have reported the in vitro cancer cell killing
effects of low dose rate radiation in comparison with high
dose rate exposures [38,39], showing that low dose rate
radiation allows repair of sublethal DNA damage during
irradiation, such that a higher total absorbed dose is
required from MRT to achieve the same proportion of cell
kill as EBRT. For example, Gholami et al. [38] compared responses to 90Y and EBRT in colorectal cancer cell lines using
a cell viability assay. It was concluded that 90Y is less potent
than EBRT, as a dose of z56 Gy from 90Y delivered over 8
days was radiobiologically equivalent to a single fraction of
z8 Gy EBRT. In a similar study by Lee et al. [39], colorectal
cancer cells were exposed to but not in direct contact with
90
Y in a set-up intended to simulate conditions during SIRT,
where 90Y-loaded microspheres are trapped in the capillary
bed of the tumour but not internalised into cancer cells. The
absorbed dose of 60 Gy from [90Y]Y-SIRT equated to doses of
17.6 and 19.3 Gy from EBRT in 10 Gy fractions (EQD10) for
two colorectal cancer cell lines. To enable combined EBRT
plus MRT treatment planning, it is necessary to include
radiobiological parameters for improved calculation of
normal tissue complication (NTCP) and tumour control
(TCP) probabilities, but few studies have incorporated NTCP
and TCP in MRT planning [40]. Van and co-workers [41]
used TCP- and NTCP-derived parameterised prescription
charts to guide clinical decision-making in patients with
HCC or metastatic liver disease treated with 90Y glass microspheres. An NTCP of 75 Gy applied to the normal liver
was shown to increase the TCP on average from 3% with
current standard doses to 22%.
Hypoxia is common in tumours because of their disordered blood supply and high oxygen consumption. As low
linear energy transfer (LET) radiation, such as conventional
photon EBRT (LET ¼ 0.3 keV/mm), is less effective in low
oxygen environments, hypoxia is a major determinant of
radioresistance. Alpha-particles, however, are densely ionising (LET ¼ 150e200 keV/mm) and their cytotoxicity has
been shown to be independent of oxygen partial pressure
[42]. This suggests a potentially useful interaction where
treatment with targeted a-particle therapy could be applied
to reduce the hypoxic fraction, followed by EBRT to more
effectively treat the normoxic tumour fraction.
Over the last few years, genome-, proteome-, and
metabolome-wide studies of the effects of ionising radiation have uncovered previously unrecognised determinants of patient- and tumour-speciﬁc radiosensitivity
[43e45]. Although these have the potential to guide
radiotherapy in the future, the application of systems
biology approaches is more challenging for radionuclide
therapy because of the relatively small size of the treated
population, which limits the number of tissue samples
available for analysis. However, the adoption of anticancer
radiopharmaceuticals for the treatment of common malignancies, such as prostate cancer, should allow meaningful analyses in the future. The potential importance of
future ‘omics’ research to MRT has been highlighted by
thought leaders in the ﬁeld and may inform how best to
combine MRT and EBRT in due course [46].

Advances in Molecular Radiotherapy
Dosimetry Facilitate Combination with
External Beam Radiotherapy
The successful combination of MRT with EBRT requires a
sound grasp of the radiation absorbed dose-effect relationship of both modalities in malignant and normal tissues. The dose-effect relationship of EBRT is based on an
extensive body of evidence that underpins clinical protocols
designed to maximise dose to tumour while avoiding
radiotoxicity in normal tissue. Equivalent evidence is largely
lacking for MRT, with the result that treatments are not
always dose-optimised. The European Association of Nuclear Medicine recently acknowledged the need for
improved prediction of efﬁcacy and adverse effects in a
position paper on the role of radiobiology and dosimetry in
nuclear medicine [46].
A major factor driving progress towards personalised
MRT dosimetry is advanced image quantiﬁcation in nuclear
medicine [47]. [90Y]Y-SIRT pre-treatment dose planning
involves SPECT imaging with a surrogate tracer, [99mTc]Tcmacroaggregated albumin, for biodistribution information.
The use of a non-identical compound for pretreatment
assessment has led to discrepancies between pre- and postSIRT dose estimates [48,49]. However, moving from SPECT
to superior resolution 90Y PET has led to more accurate 90Y
dose estimations [50,51]. Regardless of pre-treatment imaging, the tumour and normal liver absorbed dose estimation relies on post-delivery imaging. Holmium is
paramagnetic and so quantitative magnetic resonance imaging is possible with this element, giving more detailed
maps of microsphere distribution compared to SPECT/CT.
Real-time MR-guided [166Ho]Ho-SIRT could pave the way to
combination therapy with EBRT delivered using an MRLINAC [52]. A novel approach using dual isotope SPECT
imaging, combining holmium-166 microspheres as a scout
and [99mTc]Tc-colloid to identify the healthy liver, enables
automatic identiﬁcation and delineation of the tumour and
healthy tissue within a single SPECT/CT scan [53]. With
these improved imaging techniques, more accurate and
personalised calculation of radiation absorbed dose is now
possible in SIRT. This, together with the incorporation of
radiobiological modelling that accounts for differences in
the biological effects of 90Y and EBRT [54], increases the
feasibility and safety of offering SIRT as a ﬁrst option, followed by EBRT, to patients with unresectable hepatic
metastases.
Accurate MRT dosimetry is based on imaging at intervals
following administration, to track the amount of residual
radioactivity in the tumour and normal organs over time and
so calculate the total integrated dose. This approach is
resource intensive and onerous for patients as they must
attend for several scans. However, recently it has been shown
that, with prior knowledge of the biokinetics of the MRT
agent, it is possible to estimate the integrated activity and,
therefore, dose from imaging data acquired at a single time
point [55]. In a 2021 study by Hou et al. [55], the optimal
SPECT imaging time point was determined to be 72 and 48 h
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after administration of [177Lu]Lu-DOTATATE and [177Lu]Lu€nscheid
PSMA, respectively. In a 2018 study reported by Ha
et al. [56], a single time point quantitative activity measurement on SPECT/CT at 96 h post-administration of [177Lu]
Lu-DOTA-TATE or [177Lu]Lu-DOTA-TOC could be used to estimate absorbed doses. These measures to simplify dosimetry make the integration of MRT into complex
multimodality regimens more practicable.

Technological Advances that Facilitate
External Beam Radiotherapy plus
Molecular Radiotherapy Combinations
EBRT typically relies on CT imaging for the anatomical
information needed to design treatment plans that account
for variations in tissue density, which affect the absorption
of radiation dose. Standard imaging techniques for MRT
(PET/SPECT) are necessary for quantifying the distribution
of dose from direct emissions of the radionuclide source.
These imaging techniques are used together in hybrid
scanners (e.g. SPECT/CT and PET/CT) to correct for attenuation effects in MRT dosimetry. Density maps reconstructed
from CT are paired with the SPECT or PET images in
attenuation-correction algorithms, which correct for
missed counts due to scattering of ionising radiation
through dense tissues. As such, specialist hardware may aid
in precise patient-speciﬁc delivery of both EBRT and MRT. A
recent innovation, still in the development stage, is PET/CTLINAC technology, which combines PET imaging capability
with a therapy LINAC [57]. Following administration of a
tumour-seeking PET tracer, this device enables real-time
motion tracking of tumours (the radioactivity within the
tumour acts as a ﬁducial marker) and near immediate delivery of EBRT. Although the main future advantage of this
machine is predicted to be in the management of patients
with metastatic disease, as accurate EBRT of multiple sites is
facilitated, it is intriguing to speculate that a single PET
tracer could be used to plan MRT dosing and guide EBRT,
thus raising the possibility of a more harmonised approach
to dual-modality treatments.
Whole-body PET technology has moved apace in the last
few years, with the ﬁrst clinical scanners now installed [58].
As they allow low-dose imaging, rapid image acquisition
and increased sensitivity, such that tracers can be detected
for longer periods, their adoption into practice will help
streamline MRT planning [59]. The instantaneous acquisition of whole body administered activity allows total body
dosimetry analysis, which is not possible with standard
smaller ﬁeld-of-view PET systems [60].

Clinical Experience of External Beam
Radiotherapy plus Molecular Radiotherapy
Combination Protocols
Most published examples of combined MRT and EBRT
consist of retrospective series, describing patients who
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received both treatments, although not always as a preplanned dual-modality protocol. The number of reported
prospective trials that include an intention to treat with
both MRT and EBRT from the outset is small, although a few
are currently underway. A prospective clinical trial reported
in 2013 compared the analgesic effectiveness of samarium153 alone (37 MBq/kg) or combined with EBRT (8e30 Gy) in
177 prostate cancer patients with multiple painful bone
metastases [61]. Use of the Visual Analogue Pain Score
revealed complete resolution of pain in 42.5% and 62.5% of
patients in the MRT and combination arms, respectively.
Kreissl et al. [62] conducted a feasibility study of [177Lu]LuDOTA0-Tyr3-octreotate (7.0e7.9 GBq) followed by EBRT
(mean dose, 53 Gy) in 10 patients with unresectable meningioma. The treatment was well tolerated: the CTCAE
scores were <2 for all patients. In a long-term follow-up
study of the same patient cohort, the authors reported
disease stabilisation in seven of the 10 patients, with a
median progression-free survival of 107.7 months (range
47.2e111.4 months) versus 26.2 months (range 13.8e75.9
months) for patients with meningioma progression [63].
Anderson et al. [64] reported the ﬁrst use of radium-223 for
osteoblastic bone metastases from osteosarcoma in a series
of 15 patients. As well as radium-223 (55.13 kBq/kg per
cycle, up to six cycles), 12 patients received stereotactic
body radiotherapy (SBRT; mean dose, 40 Gy in ﬁve fractions) or other EBRT (45 Gy in 15 fractions) either concurrently, concurrently and sequentially or sequentially. After
radium-223, patients who had or did not have additional
EBRT had a median overall survival of 13 and 4 months,
respectively, supporting the use of combined radium-223 in
addition to EBRT. An example of a phase II trial currently
underway is the RAVENS trial (NCT04037358), in which
patients with prostate cancer and three or fewer metastases
with at least one bone metastasis are randomised to SBRT
alone or SBRT þ radium-223, with progression-free survival
as the primary end point [65]. A further phase II study
combining EBRT (pelvic volumetric modulated arc therapy)
with [177Lu]Lu-PSMA for PSMA-avid recurrent pelvic nodal
metastatic prostate cancer is planned (TARGET trial,
ACTRN12618001667202p) [66].
The ﬁnding of a sustained response to [177Lu]Lu-PSMA
has been demonstrated in relatively small volume nodal
disease in metastatic prostate cancer, both in the hormonesensitive and castrate-resistant settings [67]. In these patients, post-therapy imaging with [68Ga]Ga-PSMA PET/CT
may show a partial rather than a complete response to
treatment at some sites, such that an oligometastatic
remnant remains. In other cases, a complete metabolic
response may be seen at most sites, but stable disease or
progression at a few sites. In these circumstances, the
addition of SBRT or volumetric modulated arc therapy for
persistent or radioligand-resistant disease may be considered attractive and potentially desirable to prolong treatment response by eradicating these radioligand poorly- or
non-responsive clones. However, the long-term efﬁcacy
and outcomes from this approach have yet to be tested in a
formal trial design.
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Obstacles to Introducing Combined
Protocols
The combination of EBRT with MRT is conceptually
appealing, yet is not currently endorsed in consensus
guidelines. As noted above, the reasons for this include
empirical approaches to MRT dosimetry and the added
complexity of combining absorbed dose contributed by two
modalities. There are also organisational aspects that
explain why the two treatments have not frequently been
given together. In most healthcare systems they are delivered in different departments (nuclear medicine and radiation oncology) by different clinical teams and this has
perhaps, in the past, impeded a uniﬁed approach to
dosimetry. Combining MRT and EBRT increases the time it
takes to plan and deliver treatment. There are also practical
considerations, particularly if synchronous treatment is
envisioned: patients who have received therapeutic
amounts of radionuclides and who are to be treated
immediately with EBRT may present radiation safety problems in the radiotherapy department. Currently, most
combined treatment is not protocolised but is decided on a
case-by-case basis. Regulatory systems are ready to adapt
but this hinges on clinics intentionally adopting common
treatment combination practices and working with academic and commercial partners to solve logistical and
dosimetric challenges. A recognition that the role of therapeutic radiopharmaceuticals in cancer medicine is expanding will probably drive efﬁciencies in clinical workﬂows,
which, in turn, will facilitate more complex multimodality
treatments [68]. Managing side-effects from a combination
of EBRT and MRT is also an area with little knowledge and
expertise. Monitoring for potential cumulative toxicities
becomes paramount and managing potential cumulative
side-effects is a further practical consideration as combined
EBRT and MRT regimens are developed.

Conclusions
At present, intentional combination protocols for MRT
and EBRT do not exist as standard-of-care. Clinically
exploitable synergies between the two modalities represent
the strongest case for consolidating the costs into a single
comprehensive protocol. A call-to-action now exists for
combination EBRT and MRT to be further explored and
instituted to enhance patient outcomes.
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